好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Network Meta-Analysis for Intravenous Migraine Abortive Therapies
Headache
P6 - Poster Session 6 (11:45 AM-12:45 PM)
12-003
This network meta-analysis evaluates the effectiveness of intravenous migraine abortive medications in clinical practice, focusing on pain relief as demonstrated in randomized controlled trials.
Migraines are a recurrent, disabling headache disorder with high worldwide prevalence. Physicians use various intravenous medications to alleviate migraine pain and symptoms. However, there is a lack of consensus on the most effective intravenous abortive migraine treatments.
We searched PubMed, EMBASE, Scopus, and Cochrane (CENTRAL) for randomized controlled trials (RCTs) of intravenous migraine abortive medications in English. Non-intravenous treatments, non-migraine headaches, and studies without primary outcome measures (e.g., pain scores) were excluded. We used Rayyan for study selection and duplicate detection. We collected data on study design, sample size, treatment arms, dosages, pain outcomes, and adverse events for the included studies. We examined pain scores at baseline and 60 minutes post-treatment, using a p-score (ranges from 0–1, with closer to 1 indicating higher effectiveness) to measure the certainty that a specific treatment is superior to all other treatments in the study.
Of 5471 articles identified after deduplication, 16 studies met inclusion and exclusion criteria. Among intravenous migraine abortives studied, acetaminophen was most effective in pain reduction at 60 minutes from baseline (p-score 0.8522). Magnesium sulfate, haloperidol, and prochlorperazine followed (p-scores 0.7952, 0.7604, and 0.7057, respectively). Sumatriptan was the least effective with a p-score of 0.0805.
This network meta-analysis provides valuable information on the effectiveness of various intravenous migraine abortive drugs. Acetaminophen was the most effective for pain relief at 60 minutes. Further research is needed to corroborate these findings and examine the adverse effects of these medications.
Authors/Disclosures
Samuel Byrne
PRESENTER 		Mr. Byrne has nothing to disclose.
James Bates, Medical Student Mr. Bates has nothing to disclose.
Yuxuan Wu, MD Mr. Wu has nothing to disclose.
Nishant Satapathy Mr. Satapathy has nothing to disclose.
Rachel L. Schuurs, MD Miss Schuurs has nothing to disclose.
James Kelbert Mr. Kelbert has nothing to disclose.
Joshua Tobin, MD, FAAN (Banner University Medical Center Neurosciences Institute) An immediate family member of Dr. Tobin has received personal compensation for serving as an employee of Amgen. Dr. Tobin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Tobin has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AbbVie.